BCL2 and myeloproliferative neoplasm: The combination of JAK2 and ERK inhibition is being tested in a clinical trial (NCT04097821) for myelofibrosis [103] and perhaps combinations of MEK inhibition with BCL-2 inhibition, as well as combinations involving BET or PI3Kdelta inhibitors, could be effective therapeutic strategies in MPN.